Biotechnology

LakeShore Biopharma

LakeShore Biopharma released FY2025 earnings on July 31 (EST), actual revenue USD 85.29 M (forecast USD 111.03 M), actual EPS USD -0.7239 (forecast USD -1.495)

LakeShore Biopharma and Crystal Peak Reach Private Placement Agreement

LakeShore Biopharma Secures $15 Million in Private Placement

Akanda

Agape ATP

Co-Diagnostics

NewGenIvf

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Netcapital

PicoCELA

ATRA

SNSE

LABU

SBIO

<p>Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced positive antimicrobial resistance data for its lead candidate, Nu-3, a novel antimicrobial treatment for infected diabetic foot ulcers. The Bisphosphocin® class, to which Nu-3 belongs, has shown potential against antibiotic-resistant bacteria, maintaining efficacy even after resistance development. The global AMR crisis leads to significant mortality and healthcare costs, highlighting the need for effective treatments like Nu-3. The company aims to address the critical treatment gap for diabetic foot ulcers, which affect a substantial portion of the diabetic population.</p>

StockTitan

Atara Biotherap

Sensei Biotherapeutics

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers | LABT Stock News

LSBCF

LSBWF

<p>LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit</p>

Tip Ranks

LAKESHORE BIOPHARMA CO LTD

LAKESHORE BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD)

LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit

LakeShore Biopharma(LSB.US)

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers | LABT Stock News

LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit